Loading...
Background: Amprenavir is the fifth protease inhibitor approved by the FDA for the treatment of HIV infection. Amprenavir, like other HIV-protease inhibitors, was developed from a structure-based drug design program. It works by binding to the active site of HIV protease and inhibiting the action of this enzyme, which is critical to maturation of infectious virions. The presence of amprenavir blocks processing of viral polyprotein precursors and produces immature, noninfectious viral particles.
Pharmacology and dosing: Amprenavir is rapidly absorbed and has a half-life of 7 to 11 hours. It is metabolized in the liver by cytochrome P450-3A and is predominantly excreted by the gastrointestinal tract. Amprenavir can be taken with or without foo…